ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN) Investors of a Class Action Lawsuit and Upcoming Deadline
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm
FINAL SLRN DEADLINE: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN
SLRN Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Acelyrin, Inc. (SLRN) of Deadline in Securities Fraud Class Action Lawsuit
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm
SLRN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
ACELYRIN INVESTOR DEADLINE APPROACHING
SLRN Investors Have Opportunity to Lead ACELYRIN, Inc. Securities Fraud Lawsuit
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Acelyrin Investors of a Lead Plaintiff Deadline of January 16, 2024
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm
SLRN Investors Have Opportunity to Lead ACELYRIN, Inc. Securities Fraud Lawsuit